Skip to main content

Table 5 Tyrosine kinase inhibitors targeting the angiogenic pathway currently in clinical development in breast cancer

From: Antiangiogenic therapy for breast cancer

Drug Target
Sunitinib VEGFR2, PDGFR-β, FLT3, c-Kit
Sorafenib VEGFR1, 2 and 3, PDGFR-β, FLT3, c-Kit, Raf
Pazopanib VEGFR1, 2 and 3, PDGFR-α/β, c-Kit
Vatalanib VEGF1, 2 and 3, PDGFR, c-Kit, c-Fos
Cediranib VEFGR1, 2 and 3, PDGFR, c-Kit
Vandetanib VEGFR2, EGFR, RETS
AMG 706 VEGFR1, 2 and 3, PDGFR-β, c-kit
Axitinib VEGFR1, 2 and 3, PDGFR, c-Kit
  1. EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.